A detailed history of Bank Of Montreal transactions in Cytokinetics Inc stock. As of the latest transaction made, Bank Of Montreal holds 13,392 shares of CYTK stock, worth $743,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,392
Previous 11,665 14.8%
Holding current value
$743,256
Previous $817,000 11.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $82,654 - $129,611
1,727 Added 14.8%
13,392 $725,000
Q1 2024

May 13, 2024

SELL
$63.75 - $108.06 $28,751 - $48,735
-451 Reduced 3.72%
11,665 $817,000
Q4 2023

Feb 08, 2024

BUY
$26.88 - $83.49 $24,487 - $76,059
911 Added 8.13%
12,116 $1.01 Million
Q3 2023

Nov 01, 2023

SELL
$29.46 - $36.61 $6.87 Million - $8.53 Million
-233,104 Reduced 95.41%
11,205 $330,000
Q2 2023

Aug 02, 2023

BUY
$32.62 - $40.75 $7.65 Million - $9.55 Million
234,452 Added 2378.53%
244,309 $7.97 Million
Q1 2023

Jun 13, 2024

BUY
$33.36 - $45.71 $12.1 Million - $16.6 Million
364,154 Added 3121.77%
375,819 $13.2 Million
Q4 2022

Feb 01, 2023

SELL
$35.77 - $51.11 $17,276 - $24,686
-483 Reduced 4.67%
9,857 $451,000
Q3 2022

Nov 10, 2022

BUY
$38.54 - $54.52 $35,109 - $49,667
911 Added 9.66%
10,340 $556,000
Q2 2022

Aug 11, 2022

SELL
$33.93 - $48.92 $518,518 - $747,595
-15,282 Reduced 61.84%
9,429 $451,000
Q1 2022

May 12, 2022

BUY
$29.74 - $46.0 $13,561 - $20,976
456 Added 1.88%
24,711 $940,000
Q4 2021

Feb 11, 2022

SELL
$34.35 - $46.38 $180,440 - $243,634
-5,253 Reduced 17.8%
24,255 $1.12 Million
Q3 2021

Nov 12, 2021

BUY
$18.54 - $35.74 $58,234 - $112,259
3,141 Added 11.91%
29,508 $1.01 Million
Q2 2021

Aug 12, 2021

BUY
$19.79 - $26.99 $521,802 - $711,645
26,367 New
26,367 $598,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.22B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.